Review



hla dr pe vio 770  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Miltenyi Biotec hla dr pe vio 770
    NK cell phenotype ex vivo: ( a ) the proportion of KIR + cells in total NK cell population of HCMV − and HCMV + individuals (left), correlation between the proportion of KIR + ex vivo and the titer of antibodies to HCMV (right); ( b ) the proportion of NKG2C + cells in the NK cell population of HCMV − and HCMV + individuals (left), correlation between the proportion of NKG2C + ex vivo and the titer of antibodies to HCMV (right); ( c ) the proportion of KIR + NKG2C + cells in the NK cell population of HCMV − and HCMV + individuals (left), correlation between the proportion of KIR + NKG2C + ex vivo and the titer of antibodies to HCMV (right); ( d ) the proportions of NKG2A + , <t>HLA-DR</t> + , and HLA-DR + CD56 bright cells in the NK cell population of HCMV − and HCMV + individuals; ( e ) hierarchical tree clustering of HCMV + donors based on HLA-DR + , HLA-DR + CD56 bright , NKG2C + , NKG2A + , KIR2DL2/3 + , CD57 + NKG2C + , and KIR2DL2/3 + NKG2C + proportions in NK cell population, Ward’s method, standardized data; ( f ) the proportions of HLA-DR + CD56 bright , KIR2DL2/3 + , HLA-DR + , CD56 bright , NKG2A + , NKG2C + , CD57 + NKG2C + , and KIR2DL2/3 + NKG2C + cells in the NK cell population of different clusters’ donors. Number of donors: N = 91 (HCMV + -67, HCMV − -24). Statistical analysis was performed using nonparametric Mann–Whitney U test ( a – d ) or nonparametric Kruskal–Wallis test followed by Dunn’s multiple comparison post hoc test ( f ) (* p < 0.05, ** p < 0.01, *** p < 0.005, **** p < 0.001, ns—not significant); means ± SD are shown. Correlation analysis was done using Pearson’s correlation; p < 0.05 was considered statistically significant.
    Hla Dr Pe Vio 770, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 189 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pe+vio+770/CD159c+(NKG2C)+Antibody%2C+anti-human%2C+REAfinity/pmc13362507-252-49-53
    Average 95 stars, based on 189 article reviews
    hla dr pe vio 770 - by Bioz Stars, 2026-10
    95/100 stars

    Images

    1) Product Images from "HLA-E-Directed Accumulation of KIR + NKG2C + NK Cells upon HCMV Peptide Presentation In Vitro: Association with the Ex Vivo Phenotype"

    Article Title: HLA-E-Directed Accumulation of KIR + NKG2C + NK Cells upon HCMV Peptide Presentation In Vitro: Association with the Ex Vivo Phenotype

    Journal: International Journal of Molecular Sciences

    doi: 10.3390/ijms27136087

    NK cell phenotype ex vivo: ( a ) the proportion of KIR + cells in total NK cell population of HCMV − and HCMV + individuals (left), correlation between the proportion of KIR + ex vivo and the titer of antibodies to HCMV (right); ( b ) the proportion of NKG2C + cells in the NK cell population of HCMV − and HCMV + individuals (left), correlation between the proportion of NKG2C + ex vivo and the titer of antibodies to HCMV (right); ( c ) the proportion of KIR + NKG2C + cells in the NK cell population of HCMV − and HCMV + individuals (left), correlation between the proportion of KIR + NKG2C + ex vivo and the titer of antibodies to HCMV (right); ( d ) the proportions of NKG2A + , HLA-DR + , and HLA-DR + CD56 bright cells in the NK cell population of HCMV − and HCMV + individuals; ( e ) hierarchical tree clustering of HCMV + donors based on HLA-DR + , HLA-DR + CD56 bright , NKG2C + , NKG2A + , KIR2DL2/3 + , CD57 + NKG2C + , and KIR2DL2/3 + NKG2C + proportions in NK cell population, Ward’s method, standardized data; ( f ) the proportions of HLA-DR + CD56 bright , KIR2DL2/3 + , HLA-DR + , CD56 bright , NKG2A + , NKG2C + , CD57 + NKG2C + , and KIR2DL2/3 + NKG2C + cells in the NK cell population of different clusters’ donors. Number of donors: N = 91 (HCMV + -67, HCMV − -24). Statistical analysis was performed using nonparametric Mann–Whitney U test ( a – d ) or nonparametric Kruskal–Wallis test followed by Dunn’s multiple comparison post hoc test ( f ) (* p < 0.05, ** p < 0.01, *** p < 0.005, **** p < 0.001, ns—not significant); means ± SD are shown. Correlation analysis was done using Pearson’s correlation; p < 0.05 was considered statistically significant.
    Figure Legend Snippet: NK cell phenotype ex vivo: ( a ) the proportion of KIR + cells in total NK cell population of HCMV − and HCMV + individuals (left), correlation between the proportion of KIR + ex vivo and the titer of antibodies to HCMV (right); ( b ) the proportion of NKG2C + cells in the NK cell population of HCMV − and HCMV + individuals (left), correlation between the proportion of NKG2C + ex vivo and the titer of antibodies to HCMV (right); ( c ) the proportion of KIR + NKG2C + cells in the NK cell population of HCMV − and HCMV + individuals (left), correlation between the proportion of KIR + NKG2C + ex vivo and the titer of antibodies to HCMV (right); ( d ) the proportions of NKG2A + , HLA-DR + , and HLA-DR + CD56 bright cells in the NK cell population of HCMV − and HCMV + individuals; ( e ) hierarchical tree clustering of HCMV + donors based on HLA-DR + , HLA-DR + CD56 bright , NKG2C + , NKG2A + , KIR2DL2/3 + , CD57 + NKG2C + , and KIR2DL2/3 + NKG2C + proportions in NK cell population, Ward’s method, standardized data; ( f ) the proportions of HLA-DR + CD56 bright , KIR2DL2/3 + , HLA-DR + , CD56 bright , NKG2A + , NKG2C + , CD57 + NKG2C + , and KIR2DL2/3 + NKG2C + cells in the NK cell population of different clusters’ donors. Number of donors: N = 91 (HCMV + -67, HCMV − -24). Statistical analysis was performed using nonparametric Mann–Whitney U test ( a – d ) or nonparametric Kruskal–Wallis test followed by Dunn’s multiple comparison post hoc test ( f ) (* p < 0.05, ** p < 0.01, *** p < 0.005, **** p < 0.001, ns—not significant); means ± SD are shown. Correlation analysis was done using Pearson’s correlation; p < 0.05 was considered statistically significant.

    Techniques Used: Ex Vivo, MANN-WHITNEY, Comparison

    Proliferative activity and phenotype of bulk NK cell cultures obtained with and without LFL presentation: ( a ) expansion coefficient of bulk NK cell cultures after cultivation with and without HCMV peptide presentation, number of donors: N = 18 (HCMV + -13, HCMV − -5); ( b ) proportions of KIR + and KIR + NKG2C + cells in bulk NK cell cultures obtained with and without peptide presentation, with representative cytometric data, N = 18 (HCMV + -13, HCMV − -5); ( c ) correlation between the relative expansion coefficient K = K(LFL)/K (no peptide) and the proportion of KIR + NK cells ex vivo, N = 14 (HCMV + -9, HCMV − -5); ( d ) correlation between the expansion coefficient of NK cell cultures obtained without (left) and with (right) LFL presentation and the proportion of HLA-DR + NK cells ex vivo, N = 13 (HCMV + -8, HCMV − -5); ( e ) correlation between the relative proportion of NKG2C + (NKG2C ratio = NKG2C + ,% (LFL)/NKG2C + ,% (no peptide)) cells in cultures obtained with LFL presentation and the proportion of HLA-DR + ex vivo, N = 11 (HCMV + -6, HCMV − -5); ( f ) correlation between the relative proportion of KIR + cells (KIR ratio = KIR + ,% (LFL)/KIR + ,% (no peptide)) in cultures presented with the LFL peptide and the proportion of CD57 + NKG2C + ex vivo, N = 11 (HCMV + -6, HCMV − -5); ( g ) proportion of non-viable cells in spheroids of HLA-E-expressing tumor lines MCF7 and SKOV3 after co-incubation with bulk cultures of NK cells activated with and without peptide presentation, with representative cytometric data; 6 to 8 replicates are presented. Cultivation time T = 14 days, total number of donors: N = 18 (HCMV + -13, HCMV − -5). Statistical analysis was performed using a nonparametric Wilcoxon’s test ( b ) or nonparametric Mann–Whitney test ( a , g ) (* p < 0.05, ** p <0.01, ns—not significant); means ± SD are shown. Correlation analysis was done using Spearman’s correlation for non-normally distributed data; p < 0.05 was considered statistically significant.
    Figure Legend Snippet: Proliferative activity and phenotype of bulk NK cell cultures obtained with and without LFL presentation: ( a ) expansion coefficient of bulk NK cell cultures after cultivation with and without HCMV peptide presentation, number of donors: N = 18 (HCMV + -13, HCMV − -5); ( b ) proportions of KIR + and KIR + NKG2C + cells in bulk NK cell cultures obtained with and without peptide presentation, with representative cytometric data, N = 18 (HCMV + -13, HCMV − -5); ( c ) correlation between the relative expansion coefficient K = K(LFL)/K (no peptide) and the proportion of KIR + NK cells ex vivo, N = 14 (HCMV + -9, HCMV − -5); ( d ) correlation between the expansion coefficient of NK cell cultures obtained without (left) and with (right) LFL presentation and the proportion of HLA-DR + NK cells ex vivo, N = 13 (HCMV + -8, HCMV − -5); ( e ) correlation between the relative proportion of NKG2C + (NKG2C ratio = NKG2C + ,% (LFL)/NKG2C + ,% (no peptide)) cells in cultures obtained with LFL presentation and the proportion of HLA-DR + ex vivo, N = 11 (HCMV + -6, HCMV − -5); ( f ) correlation between the relative proportion of KIR + cells (KIR ratio = KIR + ,% (LFL)/KIR + ,% (no peptide)) in cultures presented with the LFL peptide and the proportion of CD57 + NKG2C + ex vivo, N = 11 (HCMV + -6, HCMV − -5); ( g ) proportion of non-viable cells in spheroids of HLA-E-expressing tumor lines MCF7 and SKOV3 after co-incubation with bulk cultures of NK cells activated with and without peptide presentation, with representative cytometric data; 6 to 8 replicates are presented. Cultivation time T = 14 days, total number of donors: N = 18 (HCMV + -13, HCMV − -5). Statistical analysis was performed using a nonparametric Wilcoxon’s test ( b ) or nonparametric Mann–Whitney test ( a , g ) (* p < 0.05, ** p <0.01, ns—not significant); means ± SD are shown. Correlation analysis was done using Spearman’s correlation for non-normally distributed data; p < 0.05 was considered statistically significant.

    Techniques Used: Activity Assay, Ex Vivo, Expressing, Incubation, MANN-WHITNEY

    Phenotype of NK cell subset cultures with different KIR, NKG2C, and CD57 expression profiles, activated in the presence or absence of LFL peptide: ( a ) De novo NKG2C expression in cultures of NKG2C-negative subsets with different expression of KIR and CD57, activated in the presence or absence of LFL peptide; ( b ) stability of NKG2C expression in cultures of NKG2C-positive subsets with different expression of KIR and CD57, activated in the presence or absence of LFL peptide; ( c ) de novo KIR expression in cultures of CD57 − KIR − NKG2C + subset, activated in the presence or absence of LFL; ( d ) stability of NKG2C expression in cultures of CD57 − KIR − NKG2C + , activated in the presence or absence of LFL; ( e , f ) correlation between the proportion of HLA-DR + NK cells ex vivo and the stability of KIR expression ( e ) and NKG2C de novo expression ( f ) in CD57 − KIR + NKG2C − subset cultures that were and were not presented with LFL; ( g ) correlation between the proportion of KIR + NKG2C + NK cells ex vivo and KIR de novo expression in CD57 − KIR − NKG2C + subset cultures that were and were not presented with LFL. Duration of cultivation: T = 12 days, number of donors: N = 17 (HCMV + -11, HCMV − -6). Statistical analysis was performed using a nonparametric Friedman’s test followed by Dunn’s multiple comparison post hoc test ( a , b ) or Wilcoxon’s test ( c , d ) (* p < 0.05, ** p < 0.01, ns—not significant). Correlation analysis was done using Spearman’s correlation; p < 0.05 was considered statistically significant.
    Figure Legend Snippet: Phenotype of NK cell subset cultures with different KIR, NKG2C, and CD57 expression profiles, activated in the presence or absence of LFL peptide: ( a ) De novo NKG2C expression in cultures of NKG2C-negative subsets with different expression of KIR and CD57, activated in the presence or absence of LFL peptide; ( b ) stability of NKG2C expression in cultures of NKG2C-positive subsets with different expression of KIR and CD57, activated in the presence or absence of LFL peptide; ( c ) de novo KIR expression in cultures of CD57 − KIR − NKG2C + subset, activated in the presence or absence of LFL; ( d ) stability of NKG2C expression in cultures of CD57 − KIR − NKG2C + , activated in the presence or absence of LFL; ( e , f ) correlation between the proportion of HLA-DR + NK cells ex vivo and the stability of KIR expression ( e ) and NKG2C de novo expression ( f ) in CD57 − KIR + NKG2C − subset cultures that were and were not presented with LFL; ( g ) correlation between the proportion of KIR + NKG2C + NK cells ex vivo and KIR de novo expression in CD57 − KIR − NKG2C + subset cultures that were and were not presented with LFL. Duration of cultivation: T = 12 days, number of donors: N = 17 (HCMV + -11, HCMV − -6). Statistical analysis was performed using a nonparametric Friedman’s test followed by Dunn’s multiple comparison post hoc test ( a , b ) or Wilcoxon’s test ( c , d ) (* p < 0.05, ** p < 0.01, ns—not significant). Correlation analysis was done using Spearman’s correlation; p < 0.05 was considered statistically significant.

    Techniques Used: Expressing, Ex Vivo, Comparison

    Functional activity of NK cell subset cultures with different expression of KIR, NKG2C, and CD57, activated in the presence or absence of LFL peptide: ( a ) proportion of IFNγ-producing NK cells in cultures of NKG2C-positive subsets with different expression of KIR and CD57; ( b ) proportion of IFNγ-producing NK cells in cultures of the CD57 − KIR + NKG2C − subset, to which LFL peptide was and was not presented; ( c ) proportion of degranulating CD107a + NK cells in cultures of NKG2C-positive subsets with different expression of KIR and CD57 upon co-incubation with K562 targets; ( d ) correlation between the proportion of IFNγ-producing cells in CD57 − KIR + NKG2C − subset cultures presented with LFL peptide and the proportion of NK cells NKG2C + ex vivo; ( e ) correlation between the proportion of IFNγ-producing cells in CD57 − KIR − NKG2C + subset cultures presented with LFL peptide and the proportion of NK cells KIR + NKG2C + ex vivo; ( f ) correlation between the proportion of IFNγ-producing cells in CD57 − KIR + NKG2C + subset cultures presented with LFL peptide and the proportion of NK cells KIR + NKG2C + ex vivo; ( g ) correlation between the proportion of CD107a + cells in CD57 − KIR + NKG2C + subset cultures presented with LFL peptide and the proportion of HLA-DR + NK cells in the CD56 bright fraction ex vivo; ( h ) correlation between the relative proportion of CD107a + cells in CD57 + KIR + NKG2C + subset cultures presented with LFL peptide and the proportion of HLA-DR + CD56 bright NK cells ex vivo; ( i ) correlation between the proportion of IFNγ-producing cells in CD57 − KIR + NKG2C + subset cultures presented with LFL peptide and the proportion of NKG2A + NK cells ex vivo; ( j ) correlation between the proportion of CD107a + cells in CD57 + KIR + NKG2C + subset cultures presented with the LFL peptide and the proportion of NKG2A + NK cells ex vivo. Duration of cultivation: T = 17 days, number of donors: N = 17 (HCMV + -11, HCMV − -6). Statistical analysis was performed using a nonparametric Wilcoxon’s test ( a – c ) (* p < 0.05, ** p < 0.01, ns—not significant). Correlation analysis was done using Spearman’s correlation; p < 0.05 was considered statistically significant.
    Figure Legend Snippet: Functional activity of NK cell subset cultures with different expression of KIR, NKG2C, and CD57, activated in the presence or absence of LFL peptide: ( a ) proportion of IFNγ-producing NK cells in cultures of NKG2C-positive subsets with different expression of KIR and CD57; ( b ) proportion of IFNγ-producing NK cells in cultures of the CD57 − KIR + NKG2C − subset, to which LFL peptide was and was not presented; ( c ) proportion of degranulating CD107a + NK cells in cultures of NKG2C-positive subsets with different expression of KIR and CD57 upon co-incubation with K562 targets; ( d ) correlation between the proportion of IFNγ-producing cells in CD57 − KIR + NKG2C − subset cultures presented with LFL peptide and the proportion of NK cells NKG2C + ex vivo; ( e ) correlation between the proportion of IFNγ-producing cells in CD57 − KIR − NKG2C + subset cultures presented with LFL peptide and the proportion of NK cells KIR + NKG2C + ex vivo; ( f ) correlation between the proportion of IFNγ-producing cells in CD57 − KIR + NKG2C + subset cultures presented with LFL peptide and the proportion of NK cells KIR + NKG2C + ex vivo; ( g ) correlation between the proportion of CD107a + cells in CD57 − KIR + NKG2C + subset cultures presented with LFL peptide and the proportion of HLA-DR + NK cells in the CD56 bright fraction ex vivo; ( h ) correlation between the relative proportion of CD107a + cells in CD57 + KIR + NKG2C + subset cultures presented with LFL peptide and the proportion of HLA-DR + CD56 bright NK cells ex vivo; ( i ) correlation between the proportion of IFNγ-producing cells in CD57 − KIR + NKG2C + subset cultures presented with LFL peptide and the proportion of NKG2A + NK cells ex vivo; ( j ) correlation between the proportion of CD107a + cells in CD57 + KIR + NKG2C + subset cultures presented with the LFL peptide and the proportion of NKG2A + NK cells ex vivo. Duration of cultivation: T = 17 days, number of donors: N = 17 (HCMV + -11, HCMV − -6). Statistical analysis was performed using a nonparametric Wilcoxon’s test ( a – c ) (* p < 0.05, ** p < 0.01, ns—not significant). Correlation analysis was done using Spearman’s correlation; p < 0.05 was considered statistically significant.

    Techniques Used: Functional Assay, Activity Assay, Expressing, Incubation, Ex Vivo

    Related Articles

    other:

    Article Title: Protocol for potent activation of T cells using BPI-stimulated murine bone marrow-derived cells
    Article Snippet: CD44 Antibody, anti-mouse, PE-Vio 770 clone IM7.8.1; 1:10 dilution , Miltenyi Biotec , Cat# 130-102-377 RRID: AB_2658187.

    Article Title: Nanosphere pharmacodynamics improves safety of immunostimulatory cytokine therapy
    Article Snippet: CD80 Antibody, anti-mouse, PE-Vio® 770, REAfinityTM, Clone REA983 , Miltenyi Biotech , 130-116-398; RRID: AB_2727516.

    Article Title: γδ T Cells Target and Ablate Senescent Cells in Aging and Alleviate Pulmonary Fibrosis
    Article Snippet: The following antibodies were used, CD3ε Antibody, anti-mouse, PerCP-Vio 700 (Miltenyi Biotec; Cat# 130-120-174), CD19 Antibody, anti-mouse, PE-Vio 770 (Miltenyi Biotec; Cat# 130-123-881), CD11c Antibody, anti-mouse, VioBlue (Miltenyi Biotec; Cat# 130-102-413).

    Article Title: Radiation‐induced effects on TGF‐β and PDGF receptor signaling in cancer‐associated fibroblasts
    Article Snippet: PDGFR‐β Antibody, anti‐human, PE‐Vio® 770, REAfinityTM , Miltenyi Biotec , 130‐105‐323.

    Article Title: Methods for assessing and removing non-specific photoimmunotherapy damage in patient-derived tumor cell culture models.
    Article Snippet: Anti- CD133 antibody conjugated with PE- Vio® 770 (anti- CD133–PE- Vio770), and anti- EpCAM antibody conjugated with APC- Vio® 770 (anti- EpCAM–APC- Vio770) were purchased from Miltenyi Biotec Inc. (130- 113- 749, and 130- 111- 119, respectively).

    Article Title: Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells
    Article Snippet: Ly-6C Antibody, anti-mouse, PE-Vio® 770, REAfinity , Miltenyi Biotec , Cat# 130-111-918; RRID: AB_2652810.

    Staining:

    Article Title: EpCAM–PSMA: potential predictors of treatment outcomes for PSMA-targeted alpha therapies in metastatic castration-resistant prostate cancer
    Article Snippet: .. 592 Next, the CD45-depleted samples were centrifuged at 200Xg for 5 minutes then the 593 supernatant was carefully discarded and the remaining cells were re-suspended in 594 160 μL staining-mix containing: 1.25 ng/μL Brilliant Violet 421® Streptavidin 595 (BioLegend, San Diego, USA, cat # 405226), Alexa Fluor® 488 Anti-EpCAM antibody 596 [323/A3] (Abcam, Cambridge, UK cat # ab253268) in 1:50X dilution, anti-PSMA 597 antibody REA408 – PE-Vio 770 (Miltenyi, Bergisch Gladbach, Germany, cat # 130-598 131-264) in 1:160X dilution. .. 599 The samples were incubated on ice for 60 minutes then washed with 1 mL PBS-FCS, 600 centrifuged at 200Xg for 5 minutes and re-suspended in 300 μL PBS-FCS, 601 supplemented with 120 nM DAPI (Sigma-Aldrich, St. Louis, USA, cat # D9542-10MG), 602 and 166 nM Incucyte® Caspase-3/7 Red Dye (Sartorius, Göttingen, Germany, cat # 603 4704).



    Similar Products

    hla dr pe vio 770  (Miltenyi Biotec)
    95
    Miltenyi Biotec hla dr pe vio 770
    NK cell phenotype ex vivo: ( a ) the proportion of KIR + cells in total NK cell population of HCMV − and HCMV + individuals (left), correlation between the proportion of KIR + ex vivo and the titer of antibodies to HCMV (right); ( b ) the proportion of NKG2C + cells in the NK cell population of HCMV − and HCMV + individuals (left), correlation between the proportion of NKG2C + ex vivo and the titer of antibodies to HCMV (right); ( c ) the proportion of KIR + NKG2C + cells in the NK cell population of HCMV − and HCMV + individuals (left), correlation between the proportion of KIR + NKG2C + ex vivo and the titer of antibodies to HCMV (right); ( d ) the proportions of NKG2A + , <t>HLA-DR</t> + , and HLA-DR + CD56 bright cells in the NK cell population of HCMV − and HCMV + individuals; ( e ) hierarchical tree clustering of HCMV + donors based on HLA-DR + , HLA-DR + CD56 bright , NKG2C + , NKG2A + , KIR2DL2/3 + , CD57 + NKG2C + , and KIR2DL2/3 + NKG2C + proportions in NK cell population, Ward’s method, standardized data; ( f ) the proportions of HLA-DR + CD56 bright , KIR2DL2/3 + , HLA-DR + , CD56 bright , NKG2A + , NKG2C + , CD57 + NKG2C + , and KIR2DL2/3 + NKG2C + cells in the NK cell population of different clusters’ donors. Number of donors: N = 91 (HCMV + -67, HCMV − -24). Statistical analysis was performed using nonparametric Mann–Whitney U test ( a – d ) or nonparametric Kruskal–Wallis test followed by Dunn’s multiple comparison post hoc test ( f ) (* p < 0.05, ** p < 0.01, *** p < 0.005, **** p < 0.001, ns—not significant); means ± SD are shown. Correlation analysis was done using Pearson’s correlation; p < 0.05 was considered statistically significant.
    Hla Dr Pe Vio 770, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pe+vio+770/CD159c+(NKG2C)+Antibody%2C+anti-human%2C+REAfinity/pmc13362507-252-49-53
    Average 95 stars, based on 1 article reviews
    hla dr pe vio 770 - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    cd4 pe vio 770  (Miltenyi Biotec)
    96
    Miltenyi Biotec cd4 pe vio 770
    Flow immunophenotyping release testing data are presented in A-G and IFNγ ELISpot data presented in H-K (Arm A: n = 12; Arms B/C: n = 27). Each data point represents a separate TAA-T cell product infused into patients (biological replicates). Lower whisker is defined as the minima, upper whisker is defined as the maxima, center is defined as median, lower bound of box is defined as Q1 (25th percentile), and upper bound of box is defined as Q3 (75th percentile). a ) % Total T cells (CD3 + ). Arm A: Minima=51, Maxima=99, Median=97, 25th Percentile=95, 75th Percentile=99; Arms B/C: Minima=31, Maxima=100, Median=97, 25th Percentile=94, 75th Percentile=98. b ) % <t>CD4</t> + T cells (CD3 + CD4+ of CD45 + ). Arm A: Minima=0.50, Maxima=88, Median=16, 25th Percentile=2.6, 75th Percentile=38; Arms B/C: Minima=0.40, Maxima=55, Median=9.9, 25th Percentile=6.1, 75th Percentile=17. c ) %CD8 + T cells (% CD3 + CD8+ of CD45 + ). Arm A: Minima=4.3, Maxima=88, Median=37, 25th Percentile=22, 75th Percentile=47; Arms B/C: Minima=19, Maxima=91, Median=51, 25th Percentile=36, 75th Percentile=71. d ) % αβ T cells (% TCRαβ+ of CD3 + ). Arm A: Minima=8.2, Maxima=94, Median=69, 25th Percentile=28, 75th Percentile=86; Arms B/C: Minima=32, Maxima=98, Median=71, 25th Percentile=48, 75th Percentile=84. e ) % γδ T cells (% TCRγδ+ of CD3 + ). Arm A: Minima=5.1, Maxima=79, Median=28, 25th Percentile=8.4, 75th Percentile=67; Arms B/C: Minima=1.1, Maxima=83, Median=25, 25th Percentile=10, 75th Percentile=53. f ) % CD3 + CD16 + CD56+ of CD45 + . Arm A: Minima=2.8, Maxima=25, Median=11, 25th Percentile=7.2, 75th Percentile=17; Arms B/C: Minima=3.4, Maxima=64, Median=16, 25th Percentile=8.1, 75th Percentile=28. g ) % NK cells (CD16/CD56 + CD3- of CD45 + ). Arm A: Minima=0.40, Maxima=48, Median=1.0, 25th Percentile=0.48, 75th Percentile=4.6; Arms B/C: Minima=0.10, Maxima=62, Median=1.6, 25th Percentile=0.60, 75th Percentile=6.1. h - i ) IFNγ ELISpot with background correction for Arm A ( h ) and Arms B/C ( i ). Negative values after background normalization have been normalized to zero for visual representation.
    Cd4 Pe Vio 770, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pe+vio+770/CD4+Antibody%2C+anti-human%2C+REAfinity/pmc13375545-448-86-88
    Average 96 stars, based on 1 article reviews
    cd4 pe vio 770 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    cd48 pe vio 770  (Miltenyi Biotec)
    93
    Miltenyi Biotec cd48 pe vio 770
    ( A ) Young Pnpla2 fl/fl and Pnpla2 AdipoQΔ/Δ mice were infected with MA-SARS-CoV-2 and BM was analyzed for early hematopoiesis at 5 dpi. ( B ) Representative flow cytometry plots showing c-KIT vs . Sca-1 gating on lineage-negative (Lin − ) cells to identify LKS (Lin − c-Kit + Sca-1 + ) hematopoietic stem and progenitor cells. Percentage and absolute numbers of ( C ) LKS (Lin − cKIT + Sca-1 + ) and ( D ) c-KIT + (Lin − cKIT + Sca-1 − ) cells. (E) Representative flow cytometry plots showing <t>CD48</t> vs. CD150 gating on LKS cells to identify long-term hematopoietic stem cells (LT-HSC: CD150 + CD48 − ), short-term HSC (ST-HSC: CD150 − CD48 − ) and multipotent progenitor 2 (MPP2: CD150 + CD48 + ). Percentage and absolute numbers of ( F ) LT-HSC, ( G ) ST-HSC and ( H ) MPP2 cells. ( I ) Representative flow cytometry plots showing CD135 vs . CD34 gating on MPP cells to identify MPP3 (CD135 − CD34 + ) and MPP4 (CD135 + CD34 + ). Percentage and absolute numbers of (J) MPP3 and (K) MPP4 cells. Data shown as mean ± SD (C, D, F, G, H, J, K). Circles represent individual mice (n=7-11 per group, males & females). p values determined using two-way ANOVA. NS, not significant; *p < 0.05. Data pooled from three independent experiments with a similar trend.
    Cd48 Pe Vio 770, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pe+vio+770/CD48+Antibody%2C+anti-mouse/bio_rxiv__64898__2026__06__27__734955-306-50-53
    Average 93 stars, based on 1 article reviews
    cd48 pe vio 770 - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    pe vio 770  (Miltenyi Biotec)
    94
    Miltenyi Biotec pe vio 770
    ( A ) Young Pnpla2 fl/fl and Pnpla2 AdipoQΔ/Δ mice were infected with MA-SARS-CoV-2 and BM was analyzed for early hematopoiesis at 5 dpi. ( B ) Representative flow cytometry plots showing c-KIT vs . Sca-1 gating on lineage-negative (Lin − ) cells to identify LKS (Lin − c-Kit + Sca-1 + ) hematopoietic stem and progenitor cells. Percentage and absolute numbers of ( C ) LKS (Lin − cKIT + Sca-1 + ) and ( D ) c-KIT + (Lin − cKIT + Sca-1 − ) cells. (E) Representative flow cytometry plots showing <t>CD48</t> vs. CD150 gating on LKS cells to identify long-term hematopoietic stem cells (LT-HSC: CD150 + CD48 − ), short-term HSC (ST-HSC: CD150 − CD48 − ) and multipotent progenitor 2 (MPP2: CD150 + CD48 + ). Percentage and absolute numbers of ( F ) LT-HSC, ( G ) ST-HSC and ( H ) MPP2 cells. ( I ) Representative flow cytometry plots showing CD135 vs . CD34 gating on MPP cells to identify MPP3 (CD135 − CD34 + ) and MPP4 (CD135 + CD34 + ). Percentage and absolute numbers of (J) MPP3 and (K) MPP4 cells. Data shown as mean ± SD (C, D, F, G, H, J, K). Circles represent individual mice (n=7-11 per group, males & females). p values determined using two-way ANOVA. NS, not significant; *p < 0.05. Data pooled from three independent experiments with a similar trend.
    Pe Vio 770, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pe+vio+770/CD44+Antibody%2C+anti-mouse/pmc13129426-11-3-10
    Average 94 stars, based on 1 article reviews
    pe vio 770 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    anti human cd90 pe vio 770 antibody  (Miltenyi Biotec)
    95
    Miltenyi Biotec anti human cd90 pe vio 770 antibody
    ( A ) Young Pnpla2 fl/fl and Pnpla2 AdipoQΔ/Δ mice were infected with MA-SARS-CoV-2 and BM was analyzed for early hematopoiesis at 5 dpi. ( B ) Representative flow cytometry plots showing c-KIT vs . Sca-1 gating on lineage-negative (Lin − ) cells to identify LKS (Lin − c-Kit + Sca-1 + ) hematopoietic stem and progenitor cells. Percentage and absolute numbers of ( C ) LKS (Lin − cKIT + Sca-1 + ) and ( D ) c-KIT + (Lin − cKIT + Sca-1 − ) cells. (E) Representative flow cytometry plots showing <t>CD48</t> vs. CD150 gating on LKS cells to identify long-term hematopoietic stem cells (LT-HSC: CD150 + CD48 − ), short-term HSC (ST-HSC: CD150 − CD48 − ) and multipotent progenitor 2 (MPP2: CD150 + CD48 + ). Percentage and absolute numbers of ( F ) LT-HSC, ( G ) ST-HSC and ( H ) MPP2 cells. ( I ) Representative flow cytometry plots showing CD135 vs . CD34 gating on MPP cells to identify MPP3 (CD135 − CD34 + ) and MPP4 (CD135 + CD34 + ). Percentage and absolute numbers of (J) MPP3 and (K) MPP4 cells. Data shown as mean ± SD (C, D, F, G, H, J, K). Circles represent individual mice (n=7-11 per group, males & females). p values determined using two-way ANOVA. NS, not significant; *p < 0.05. Data pooled from three independent experiments with a similar trend.
    Anti Human Cd90 Pe Vio 770 Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pe+vio+770/CD90+Antibody%2C+anti-human%2C+REAfinity/us12624338-749-6-5
    Average 95 stars, based on 1 article reviews
    anti human cd90 pe vio 770 antibody - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    anti mouse cd4 pe vio 770  (Miltenyi Biotec)
    96
    Miltenyi Biotec anti mouse cd4 pe vio 770
    ( A ) Young Pnpla2 fl/fl and Pnpla2 AdipoQΔ/Δ mice were infected with MA-SARS-CoV-2 and BM was analyzed for early hematopoiesis at 5 dpi. ( B ) Representative flow cytometry plots showing c-KIT vs . Sca-1 gating on lineage-negative (Lin − ) cells to identify LKS (Lin − c-Kit + Sca-1 + ) hematopoietic stem and progenitor cells. Percentage and absolute numbers of ( C ) LKS (Lin − cKIT + Sca-1 + ) and ( D ) c-KIT + (Lin − cKIT + Sca-1 − ) cells. (E) Representative flow cytometry plots showing <t>CD48</t> vs. CD150 gating on LKS cells to identify long-term hematopoietic stem cells (LT-HSC: CD150 + CD48 − ), short-term HSC (ST-HSC: CD150 − CD48 − ) and multipotent progenitor 2 (MPP2: CD150 + CD48 + ). Percentage and absolute numbers of ( F ) LT-HSC, ( G ) ST-HSC and ( H ) MPP2 cells. ( I ) Representative flow cytometry plots showing CD135 vs . CD34 gating on MPP cells to identify MPP3 (CD135 − CD34 + ) and MPP4 (CD135 + CD34 + ). Percentage and absolute numbers of (J) MPP3 and (K) MPP4 cells. Data shown as mean ± SD (C, D, F, G, H, J, K). Circles represent individual mice (n=7-11 per group, males & females). p values determined using two-way ANOVA. NS, not significant; *p < 0.05. Data pooled from three independent experiments with a similar trend.
    Anti Mouse Cd4 Pe Vio 770, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pe+vio+770/CD4+Antibody%2C+anti-mouse/pm41888511-227-46-51
    Average 96 stars, based on 1 article reviews
    anti mouse cd4 pe vio 770 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    pe vio 770 anti mouse hsp 70  (Miltenyi Biotec)
    94
    Miltenyi Biotec pe vio 770 anti mouse hsp 70
    ( A ) Young Pnpla2 fl/fl and Pnpla2 AdipoQΔ/Δ mice were infected with MA-SARS-CoV-2 and BM was analyzed for early hematopoiesis at 5 dpi. ( B ) Representative flow cytometry plots showing c-KIT vs . Sca-1 gating on lineage-negative (Lin − ) cells to identify LKS (Lin − c-Kit + Sca-1 + ) hematopoietic stem and progenitor cells. Percentage and absolute numbers of ( C ) LKS (Lin − cKIT + Sca-1 + ) and ( D ) c-KIT + (Lin − cKIT + Sca-1 − ) cells. (E) Representative flow cytometry plots showing <t>CD48</t> vs. CD150 gating on LKS cells to identify long-term hematopoietic stem cells (LT-HSC: CD150 + CD48 − ), short-term HSC (ST-HSC: CD150 − CD48 − ) and multipotent progenitor 2 (MPP2: CD150 + CD48 + ). Percentage and absolute numbers of ( F ) LT-HSC, ( G ) ST-HSC and ( H ) MPP2 cells. ( I ) Representative flow cytometry plots showing CD135 vs . CD34 gating on MPP cells to identify MPP3 (CD135 − CD34 + ) and MPP4 (CD135 + CD34 + ). Percentage and absolute numbers of (J) MPP3 and (K) MPP4 cells. Data shown as mean ± SD (C, D, F, G, H, J, K). Circles represent individual mice (n=7-11 per group, males & females). p values determined using two-way ANOVA. NS, not significant; *p < 0.05. Data pooled from three independent experiments with a similar trend.
    Pe Vio 770 Anti Mouse Hsp 70, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pe+vio+770/Hsp70+Antibody%2C+anti-human%2Fmouse%2C+REAfinity/pmc13006431-75-0-6
    Average 94 stars, based on 1 article reviews
    pe vio 770 anti mouse hsp 70 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    cd25 pe vio 770  (Miltenyi Biotec)
    96
    Miltenyi Biotec cd25 pe vio 770
    ( A ) Young Pnpla2 fl/fl and Pnpla2 AdipoQΔ/Δ mice were infected with MA-SARS-CoV-2 and BM was analyzed for early hematopoiesis at 5 dpi. ( B ) Representative flow cytometry plots showing c-KIT vs . Sca-1 gating on lineage-negative (Lin − ) cells to identify LKS (Lin − c-Kit + Sca-1 + ) hematopoietic stem and progenitor cells. Percentage and absolute numbers of ( C ) LKS (Lin − cKIT + Sca-1 + ) and ( D ) c-KIT + (Lin − cKIT + Sca-1 − ) cells. (E) Representative flow cytometry plots showing <t>CD48</t> vs. CD150 gating on LKS cells to identify long-term hematopoietic stem cells (LT-HSC: CD150 + CD48 − ), short-term HSC (ST-HSC: CD150 − CD48 − ) and multipotent progenitor 2 (MPP2: CD150 + CD48 + ). Percentage and absolute numbers of ( F ) LT-HSC, ( G ) ST-HSC and ( H ) MPP2 cells. ( I ) Representative flow cytometry plots showing CD135 vs . CD34 gating on MPP cells to identify MPP3 (CD135 − CD34 + ) and MPP4 (CD135 + CD34 + ). Percentage and absolute numbers of (J) MPP3 and (K) MPP4 cells. Data shown as mean ± SD (C, D, F, G, H, J, K). Circles represent individual mice (n=7-11 per group, males & females). p values determined using two-way ANOVA. NS, not significant; *p < 0.05. Data pooled from three independent experiments with a similar trend.
    Cd25 Pe Vio 770, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pe+vio+770/CD25-PE/pmc13006440-383-42-47
    Average 96 stars, based on 1 article reviews
    cd25 pe vio 770 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    acsa2 pe vio 770  (Miltenyi Biotec)
    96
    Miltenyi Biotec acsa2 pe vio 770
    ( A ) Young Pnpla2 fl/fl and Pnpla2 AdipoQΔ/Δ mice were infected with MA-SARS-CoV-2 and BM was analyzed for early hematopoiesis at 5 dpi. ( B ) Representative flow cytometry plots showing c-KIT vs . Sca-1 gating on lineage-negative (Lin − ) cells to identify LKS (Lin − c-Kit + Sca-1 + ) hematopoietic stem and progenitor cells. Percentage and absolute numbers of ( C ) LKS (Lin − cKIT + Sca-1 + ) and ( D ) c-KIT + (Lin − cKIT + Sca-1 − ) cells. (E) Representative flow cytometry plots showing <t>CD48</t> vs. CD150 gating on LKS cells to identify long-term hematopoietic stem cells (LT-HSC: CD150 + CD48 − ), short-term HSC (ST-HSC: CD150 − CD48 − ) and multipotent progenitor 2 (MPP2: CD150 + CD48 + ). Percentage and absolute numbers of ( F ) LT-HSC, ( G ) ST-HSC and ( H ) MPP2 cells. ( I ) Representative flow cytometry plots showing CD135 vs . CD34 gating on MPP cells to identify MPP3 (CD135 − CD34 + ) and MPP4 (CD135 + CD34 + ). Percentage and absolute numbers of (J) MPP3 and (K) MPP4 cells. Data shown as mean ± SD (C, D, F, G, H, J, K). Circles represent individual mice (n=7-11 per group, males & females). p values determined using two-way ANOVA. NS, not significant; *p < 0.05. Data pooled from three independent experiments with a similar trend.
    Acsa2 Pe Vio 770, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pe+vio+770/ACSA-2+Antibody%2C+anti-mouse%2C+REAfinity/bio_rxiv__64898__2026__03__11__710967-77-28-31
    Average 96 stars, based on 1 article reviews
    acsa2 pe vio 770 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    NK cell phenotype ex vivo: ( a ) the proportion of KIR + cells in total NK cell population of HCMV − and HCMV + individuals (left), correlation between the proportion of KIR + ex vivo and the titer of antibodies to HCMV (right); ( b ) the proportion of NKG2C + cells in the NK cell population of HCMV − and HCMV + individuals (left), correlation between the proportion of NKG2C + ex vivo and the titer of antibodies to HCMV (right); ( c ) the proportion of KIR + NKG2C + cells in the NK cell population of HCMV − and HCMV + individuals (left), correlation between the proportion of KIR + NKG2C + ex vivo and the titer of antibodies to HCMV (right); ( d ) the proportions of NKG2A + , HLA-DR + , and HLA-DR + CD56 bright cells in the NK cell population of HCMV − and HCMV + individuals; ( e ) hierarchical tree clustering of HCMV + donors based on HLA-DR + , HLA-DR + CD56 bright , NKG2C + , NKG2A + , KIR2DL2/3 + , CD57 + NKG2C + , and KIR2DL2/3 + NKG2C + proportions in NK cell population, Ward’s method, standardized data; ( f ) the proportions of HLA-DR + CD56 bright , KIR2DL2/3 + , HLA-DR + , CD56 bright , NKG2A + , NKG2C + , CD57 + NKG2C + , and KIR2DL2/3 + NKG2C + cells in the NK cell population of different clusters’ donors. Number of donors: N = 91 (HCMV + -67, HCMV − -24). Statistical analysis was performed using nonparametric Mann–Whitney U test ( a – d ) or nonparametric Kruskal–Wallis test followed by Dunn’s multiple comparison post hoc test ( f ) (* p < 0.05, ** p < 0.01, *** p < 0.005, **** p < 0.001, ns—not significant); means ± SD are shown. Correlation analysis was done using Pearson’s correlation; p < 0.05 was considered statistically significant.

    Journal: International Journal of Molecular Sciences

    Article Title: HLA-E-Directed Accumulation of KIR + NKG2C + NK Cells upon HCMV Peptide Presentation In Vitro: Association with the Ex Vivo Phenotype

    doi: 10.3390/ijms27136087

    Figure Lengend Snippet: NK cell phenotype ex vivo: ( a ) the proportion of KIR + cells in total NK cell population of HCMV − and HCMV + individuals (left), correlation between the proportion of KIR + ex vivo and the titer of antibodies to HCMV (right); ( b ) the proportion of NKG2C + cells in the NK cell population of HCMV − and HCMV + individuals (left), correlation between the proportion of NKG2C + ex vivo and the titer of antibodies to HCMV (right); ( c ) the proportion of KIR + NKG2C + cells in the NK cell population of HCMV − and HCMV + individuals (left), correlation between the proportion of KIR + NKG2C + ex vivo and the titer of antibodies to HCMV (right); ( d ) the proportions of NKG2A + , HLA-DR + , and HLA-DR + CD56 bright cells in the NK cell population of HCMV − and HCMV + individuals; ( e ) hierarchical tree clustering of HCMV + donors based on HLA-DR + , HLA-DR + CD56 bright , NKG2C + , NKG2A + , KIR2DL2/3 + , CD57 + NKG2C + , and KIR2DL2/3 + NKG2C + proportions in NK cell population, Ward’s method, standardized data; ( f ) the proportions of HLA-DR + CD56 bright , KIR2DL2/3 + , HLA-DR + , CD56 bright , NKG2A + , NKG2C + , CD57 + NKG2C + , and KIR2DL2/3 + NKG2C + cells in the NK cell population of different clusters’ donors. Number of donors: N = 91 (HCMV + -67, HCMV − -24). Statistical analysis was performed using nonparametric Mann–Whitney U test ( a – d ) or nonparametric Kruskal–Wallis test followed by Dunn’s multiple comparison post hoc test ( f ) (* p < 0.05, ** p < 0.01, *** p < 0.005, **** p < 0.001, ns—not significant); means ± SD are shown. Correlation analysis was done using Pearson’s correlation; p < 0.05 was considered statistically significant.

    Article Snippet: Mouse anti-human fluorescent-labeled antibodies that were used for PBMC/NK cell surface staining were as follows: CD3-APC-Vio 770 (Clone REA613), CD56-FITC, CD56-PE-Vio 615, CD56-PE-Vio 770 (Clone REA196), CD57-VioBlue, CD57-APC-Vio 770 (Clone TB03), KIR2DL2/3-FITC, KIR2DL2/3-PE-Vio 615 (Clone REA 1006), KIR2DL2/3-APC (Clone DX27), NKG2A-PE, NKG2A-PE-Vio 770 (Clone REA110), NKG2C-FITC, NKG2C-PE (Clone REA205), HLA-DR-PE-Vio 770 (Clone REA805) (Miltenyi Biotech); CD3-PerCP (Clone HIT3a), CD56-Brilliant Violet 421 (Clone 5.1H11) (Sony, San Jose, CA, USA) (also shown in ).

    Techniques: Ex Vivo, MANN-WHITNEY, Comparison

    Proliferative activity and phenotype of bulk NK cell cultures obtained with and without LFL presentation: ( a ) expansion coefficient of bulk NK cell cultures after cultivation with and without HCMV peptide presentation, number of donors: N = 18 (HCMV + -13, HCMV − -5); ( b ) proportions of KIR + and KIR + NKG2C + cells in bulk NK cell cultures obtained with and without peptide presentation, with representative cytometric data, N = 18 (HCMV + -13, HCMV − -5); ( c ) correlation between the relative expansion coefficient K = K(LFL)/K (no peptide) and the proportion of KIR + NK cells ex vivo, N = 14 (HCMV + -9, HCMV − -5); ( d ) correlation between the expansion coefficient of NK cell cultures obtained without (left) and with (right) LFL presentation and the proportion of HLA-DR + NK cells ex vivo, N = 13 (HCMV + -8, HCMV − -5); ( e ) correlation between the relative proportion of NKG2C + (NKG2C ratio = NKG2C + ,% (LFL)/NKG2C + ,% (no peptide)) cells in cultures obtained with LFL presentation and the proportion of HLA-DR + ex vivo, N = 11 (HCMV + -6, HCMV − -5); ( f ) correlation between the relative proportion of KIR + cells (KIR ratio = KIR + ,% (LFL)/KIR + ,% (no peptide)) in cultures presented with the LFL peptide and the proportion of CD57 + NKG2C + ex vivo, N = 11 (HCMV + -6, HCMV − -5); ( g ) proportion of non-viable cells in spheroids of HLA-E-expressing tumor lines MCF7 and SKOV3 after co-incubation with bulk cultures of NK cells activated with and without peptide presentation, with representative cytometric data; 6 to 8 replicates are presented. Cultivation time T = 14 days, total number of donors: N = 18 (HCMV + -13, HCMV − -5). Statistical analysis was performed using a nonparametric Wilcoxon’s test ( b ) or nonparametric Mann–Whitney test ( a , g ) (* p < 0.05, ** p <0.01, ns—not significant); means ± SD are shown. Correlation analysis was done using Spearman’s correlation for non-normally distributed data; p < 0.05 was considered statistically significant.

    Journal: International Journal of Molecular Sciences

    Article Title: HLA-E-Directed Accumulation of KIR + NKG2C + NK Cells upon HCMV Peptide Presentation In Vitro: Association with the Ex Vivo Phenotype

    doi: 10.3390/ijms27136087

    Figure Lengend Snippet: Proliferative activity and phenotype of bulk NK cell cultures obtained with and without LFL presentation: ( a ) expansion coefficient of bulk NK cell cultures after cultivation with and without HCMV peptide presentation, number of donors: N = 18 (HCMV + -13, HCMV − -5); ( b ) proportions of KIR + and KIR + NKG2C + cells in bulk NK cell cultures obtained with and without peptide presentation, with representative cytometric data, N = 18 (HCMV + -13, HCMV − -5); ( c ) correlation between the relative expansion coefficient K = K(LFL)/K (no peptide) and the proportion of KIR + NK cells ex vivo, N = 14 (HCMV + -9, HCMV − -5); ( d ) correlation between the expansion coefficient of NK cell cultures obtained without (left) and with (right) LFL presentation and the proportion of HLA-DR + NK cells ex vivo, N = 13 (HCMV + -8, HCMV − -5); ( e ) correlation between the relative proportion of NKG2C + (NKG2C ratio = NKG2C + ,% (LFL)/NKG2C + ,% (no peptide)) cells in cultures obtained with LFL presentation and the proportion of HLA-DR + ex vivo, N = 11 (HCMV + -6, HCMV − -5); ( f ) correlation between the relative proportion of KIR + cells (KIR ratio = KIR + ,% (LFL)/KIR + ,% (no peptide)) in cultures presented with the LFL peptide and the proportion of CD57 + NKG2C + ex vivo, N = 11 (HCMV + -6, HCMV − -5); ( g ) proportion of non-viable cells in spheroids of HLA-E-expressing tumor lines MCF7 and SKOV3 after co-incubation with bulk cultures of NK cells activated with and without peptide presentation, with representative cytometric data; 6 to 8 replicates are presented. Cultivation time T = 14 days, total number of donors: N = 18 (HCMV + -13, HCMV − -5). Statistical analysis was performed using a nonparametric Wilcoxon’s test ( b ) or nonparametric Mann–Whitney test ( a , g ) (* p < 0.05, ** p <0.01, ns—not significant); means ± SD are shown. Correlation analysis was done using Spearman’s correlation for non-normally distributed data; p < 0.05 was considered statistically significant.

    Article Snippet: Mouse anti-human fluorescent-labeled antibodies that were used for PBMC/NK cell surface staining were as follows: CD3-APC-Vio 770 (Clone REA613), CD56-FITC, CD56-PE-Vio 615, CD56-PE-Vio 770 (Clone REA196), CD57-VioBlue, CD57-APC-Vio 770 (Clone TB03), KIR2DL2/3-FITC, KIR2DL2/3-PE-Vio 615 (Clone REA 1006), KIR2DL2/3-APC (Clone DX27), NKG2A-PE, NKG2A-PE-Vio 770 (Clone REA110), NKG2C-FITC, NKG2C-PE (Clone REA205), HLA-DR-PE-Vio 770 (Clone REA805) (Miltenyi Biotech); CD3-PerCP (Clone HIT3a), CD56-Brilliant Violet 421 (Clone 5.1H11) (Sony, San Jose, CA, USA) (also shown in ).

    Techniques: Activity Assay, Ex Vivo, Expressing, Incubation, MANN-WHITNEY

    Phenotype of NK cell subset cultures with different KIR, NKG2C, and CD57 expression profiles, activated in the presence or absence of LFL peptide: ( a ) De novo NKG2C expression in cultures of NKG2C-negative subsets with different expression of KIR and CD57, activated in the presence or absence of LFL peptide; ( b ) stability of NKG2C expression in cultures of NKG2C-positive subsets with different expression of KIR and CD57, activated in the presence or absence of LFL peptide; ( c ) de novo KIR expression in cultures of CD57 − KIR − NKG2C + subset, activated in the presence or absence of LFL; ( d ) stability of NKG2C expression in cultures of CD57 − KIR − NKG2C + , activated in the presence or absence of LFL; ( e , f ) correlation between the proportion of HLA-DR + NK cells ex vivo and the stability of KIR expression ( e ) and NKG2C de novo expression ( f ) in CD57 − KIR + NKG2C − subset cultures that were and were not presented with LFL; ( g ) correlation between the proportion of KIR + NKG2C + NK cells ex vivo and KIR de novo expression in CD57 − KIR − NKG2C + subset cultures that were and were not presented with LFL. Duration of cultivation: T = 12 days, number of donors: N = 17 (HCMV + -11, HCMV − -6). Statistical analysis was performed using a nonparametric Friedman’s test followed by Dunn’s multiple comparison post hoc test ( a , b ) or Wilcoxon’s test ( c , d ) (* p < 0.05, ** p < 0.01, ns—not significant). Correlation analysis was done using Spearman’s correlation; p < 0.05 was considered statistically significant.

    Journal: International Journal of Molecular Sciences

    Article Title: HLA-E-Directed Accumulation of KIR + NKG2C + NK Cells upon HCMV Peptide Presentation In Vitro: Association with the Ex Vivo Phenotype

    doi: 10.3390/ijms27136087

    Figure Lengend Snippet: Phenotype of NK cell subset cultures with different KIR, NKG2C, and CD57 expression profiles, activated in the presence or absence of LFL peptide: ( a ) De novo NKG2C expression in cultures of NKG2C-negative subsets with different expression of KIR and CD57, activated in the presence or absence of LFL peptide; ( b ) stability of NKG2C expression in cultures of NKG2C-positive subsets with different expression of KIR and CD57, activated in the presence or absence of LFL peptide; ( c ) de novo KIR expression in cultures of CD57 − KIR − NKG2C + subset, activated in the presence or absence of LFL; ( d ) stability of NKG2C expression in cultures of CD57 − KIR − NKG2C + , activated in the presence or absence of LFL; ( e , f ) correlation between the proportion of HLA-DR + NK cells ex vivo and the stability of KIR expression ( e ) and NKG2C de novo expression ( f ) in CD57 − KIR + NKG2C − subset cultures that were and were not presented with LFL; ( g ) correlation between the proportion of KIR + NKG2C + NK cells ex vivo and KIR de novo expression in CD57 − KIR − NKG2C + subset cultures that were and were not presented with LFL. Duration of cultivation: T = 12 days, number of donors: N = 17 (HCMV + -11, HCMV − -6). Statistical analysis was performed using a nonparametric Friedman’s test followed by Dunn’s multiple comparison post hoc test ( a , b ) or Wilcoxon’s test ( c , d ) (* p < 0.05, ** p < 0.01, ns—not significant). Correlation analysis was done using Spearman’s correlation; p < 0.05 was considered statistically significant.

    Article Snippet: Mouse anti-human fluorescent-labeled antibodies that were used for PBMC/NK cell surface staining were as follows: CD3-APC-Vio 770 (Clone REA613), CD56-FITC, CD56-PE-Vio 615, CD56-PE-Vio 770 (Clone REA196), CD57-VioBlue, CD57-APC-Vio 770 (Clone TB03), KIR2DL2/3-FITC, KIR2DL2/3-PE-Vio 615 (Clone REA 1006), KIR2DL2/3-APC (Clone DX27), NKG2A-PE, NKG2A-PE-Vio 770 (Clone REA110), NKG2C-FITC, NKG2C-PE (Clone REA205), HLA-DR-PE-Vio 770 (Clone REA805) (Miltenyi Biotech); CD3-PerCP (Clone HIT3a), CD56-Brilliant Violet 421 (Clone 5.1H11) (Sony, San Jose, CA, USA) (also shown in ).

    Techniques: Expressing, Ex Vivo, Comparison

    Functional activity of NK cell subset cultures with different expression of KIR, NKG2C, and CD57, activated in the presence or absence of LFL peptide: ( a ) proportion of IFNγ-producing NK cells in cultures of NKG2C-positive subsets with different expression of KIR and CD57; ( b ) proportion of IFNγ-producing NK cells in cultures of the CD57 − KIR + NKG2C − subset, to which LFL peptide was and was not presented; ( c ) proportion of degranulating CD107a + NK cells in cultures of NKG2C-positive subsets with different expression of KIR and CD57 upon co-incubation with K562 targets; ( d ) correlation between the proportion of IFNγ-producing cells in CD57 − KIR + NKG2C − subset cultures presented with LFL peptide and the proportion of NK cells NKG2C + ex vivo; ( e ) correlation between the proportion of IFNγ-producing cells in CD57 − KIR − NKG2C + subset cultures presented with LFL peptide and the proportion of NK cells KIR + NKG2C + ex vivo; ( f ) correlation between the proportion of IFNγ-producing cells in CD57 − KIR + NKG2C + subset cultures presented with LFL peptide and the proportion of NK cells KIR + NKG2C + ex vivo; ( g ) correlation between the proportion of CD107a + cells in CD57 − KIR + NKG2C + subset cultures presented with LFL peptide and the proportion of HLA-DR + NK cells in the CD56 bright fraction ex vivo; ( h ) correlation between the relative proportion of CD107a + cells in CD57 + KIR + NKG2C + subset cultures presented with LFL peptide and the proportion of HLA-DR + CD56 bright NK cells ex vivo; ( i ) correlation between the proportion of IFNγ-producing cells in CD57 − KIR + NKG2C + subset cultures presented with LFL peptide and the proportion of NKG2A + NK cells ex vivo; ( j ) correlation between the proportion of CD107a + cells in CD57 + KIR + NKG2C + subset cultures presented with the LFL peptide and the proportion of NKG2A + NK cells ex vivo. Duration of cultivation: T = 17 days, number of donors: N = 17 (HCMV + -11, HCMV − -6). Statistical analysis was performed using a nonparametric Wilcoxon’s test ( a – c ) (* p < 0.05, ** p < 0.01, ns—not significant). Correlation analysis was done using Spearman’s correlation; p < 0.05 was considered statistically significant.

    Journal: International Journal of Molecular Sciences

    Article Title: HLA-E-Directed Accumulation of KIR + NKG2C + NK Cells upon HCMV Peptide Presentation In Vitro: Association with the Ex Vivo Phenotype

    doi: 10.3390/ijms27136087

    Figure Lengend Snippet: Functional activity of NK cell subset cultures with different expression of KIR, NKG2C, and CD57, activated in the presence or absence of LFL peptide: ( a ) proportion of IFNγ-producing NK cells in cultures of NKG2C-positive subsets with different expression of KIR and CD57; ( b ) proportion of IFNγ-producing NK cells in cultures of the CD57 − KIR + NKG2C − subset, to which LFL peptide was and was not presented; ( c ) proportion of degranulating CD107a + NK cells in cultures of NKG2C-positive subsets with different expression of KIR and CD57 upon co-incubation with K562 targets; ( d ) correlation between the proportion of IFNγ-producing cells in CD57 − KIR + NKG2C − subset cultures presented with LFL peptide and the proportion of NK cells NKG2C + ex vivo; ( e ) correlation between the proportion of IFNγ-producing cells in CD57 − KIR − NKG2C + subset cultures presented with LFL peptide and the proportion of NK cells KIR + NKG2C + ex vivo; ( f ) correlation between the proportion of IFNγ-producing cells in CD57 − KIR + NKG2C + subset cultures presented with LFL peptide and the proportion of NK cells KIR + NKG2C + ex vivo; ( g ) correlation between the proportion of CD107a + cells in CD57 − KIR + NKG2C + subset cultures presented with LFL peptide and the proportion of HLA-DR + NK cells in the CD56 bright fraction ex vivo; ( h ) correlation between the relative proportion of CD107a + cells in CD57 + KIR + NKG2C + subset cultures presented with LFL peptide and the proportion of HLA-DR + CD56 bright NK cells ex vivo; ( i ) correlation between the proportion of IFNγ-producing cells in CD57 − KIR + NKG2C + subset cultures presented with LFL peptide and the proportion of NKG2A + NK cells ex vivo; ( j ) correlation between the proportion of CD107a + cells in CD57 + KIR + NKG2C + subset cultures presented with the LFL peptide and the proportion of NKG2A + NK cells ex vivo. Duration of cultivation: T = 17 days, number of donors: N = 17 (HCMV + -11, HCMV − -6). Statistical analysis was performed using a nonparametric Wilcoxon’s test ( a – c ) (* p < 0.05, ** p < 0.01, ns—not significant). Correlation analysis was done using Spearman’s correlation; p < 0.05 was considered statistically significant.

    Article Snippet: Mouse anti-human fluorescent-labeled antibodies that were used for PBMC/NK cell surface staining were as follows: CD3-APC-Vio 770 (Clone REA613), CD56-FITC, CD56-PE-Vio 615, CD56-PE-Vio 770 (Clone REA196), CD57-VioBlue, CD57-APC-Vio 770 (Clone TB03), KIR2DL2/3-FITC, KIR2DL2/3-PE-Vio 615 (Clone REA 1006), KIR2DL2/3-APC (Clone DX27), NKG2A-PE, NKG2A-PE-Vio 770 (Clone REA110), NKG2C-FITC, NKG2C-PE (Clone REA205), HLA-DR-PE-Vio 770 (Clone REA805) (Miltenyi Biotech); CD3-PerCP (Clone HIT3a), CD56-Brilliant Violet 421 (Clone 5.1H11) (Sony, San Jose, CA, USA) (also shown in ).

    Techniques: Functional Assay, Activity Assay, Expressing, Incubation, Ex Vivo

    Flow immunophenotyping release testing data are presented in A-G and IFNγ ELISpot data presented in H-K (Arm A: n = 12; Arms B/C: n = 27). Each data point represents a separate TAA-T cell product infused into patients (biological replicates). Lower whisker is defined as the minima, upper whisker is defined as the maxima, center is defined as median, lower bound of box is defined as Q1 (25th percentile), and upper bound of box is defined as Q3 (75th percentile). a ) % Total T cells (CD3 + ). Arm A: Minima=51, Maxima=99, Median=97, 25th Percentile=95, 75th Percentile=99; Arms B/C: Minima=31, Maxima=100, Median=97, 25th Percentile=94, 75th Percentile=98. b ) % CD4 + T cells (CD3 + CD4+ of CD45 + ). Arm A: Minima=0.50, Maxima=88, Median=16, 25th Percentile=2.6, 75th Percentile=38; Arms B/C: Minima=0.40, Maxima=55, Median=9.9, 25th Percentile=6.1, 75th Percentile=17. c ) %CD8 + T cells (% CD3 + CD8+ of CD45 + ). Arm A: Minima=4.3, Maxima=88, Median=37, 25th Percentile=22, 75th Percentile=47; Arms B/C: Minima=19, Maxima=91, Median=51, 25th Percentile=36, 75th Percentile=71. d ) % αβ T cells (% TCRαβ+ of CD3 + ). Arm A: Minima=8.2, Maxima=94, Median=69, 25th Percentile=28, 75th Percentile=86; Arms B/C: Minima=32, Maxima=98, Median=71, 25th Percentile=48, 75th Percentile=84. e ) % γδ T cells (% TCRγδ+ of CD3 + ). Arm A: Minima=5.1, Maxima=79, Median=28, 25th Percentile=8.4, 75th Percentile=67; Arms B/C: Minima=1.1, Maxima=83, Median=25, 25th Percentile=10, 75th Percentile=53. f ) % CD3 + CD16 + CD56+ of CD45 + . Arm A: Minima=2.8, Maxima=25, Median=11, 25th Percentile=7.2, 75th Percentile=17; Arms B/C: Minima=3.4, Maxima=64, Median=16, 25th Percentile=8.1, 75th Percentile=28. g ) % NK cells (CD16/CD56 + CD3- of CD45 + ). Arm A: Minima=0.40, Maxima=48, Median=1.0, 25th Percentile=0.48, 75th Percentile=4.6; Arms B/C: Minima=0.10, Maxima=62, Median=1.6, 25th Percentile=0.60, 75th Percentile=6.1. h - i ) IFNγ ELISpot with background correction for Arm A ( h ) and Arms B/C ( i ). Negative values after background normalization have been normalized to zero for visual representation.

    Journal: Nature Medicine

    Article Title: Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial

    doi: 10.1038/s41591-026-04449-9

    Figure Lengend Snippet: Flow immunophenotyping release testing data are presented in A-G and IFNγ ELISpot data presented in H-K (Arm A: n = 12; Arms B/C: n = 27). Each data point represents a separate TAA-T cell product infused into patients (biological replicates). Lower whisker is defined as the minima, upper whisker is defined as the maxima, center is defined as median, lower bound of box is defined as Q1 (25th percentile), and upper bound of box is defined as Q3 (75th percentile). a ) % Total T cells (CD3 + ). Arm A: Minima=51, Maxima=99, Median=97, 25th Percentile=95, 75th Percentile=99; Arms B/C: Minima=31, Maxima=100, Median=97, 25th Percentile=94, 75th Percentile=98. b ) % CD4 + T cells (CD3 + CD4+ of CD45 + ). Arm A: Minima=0.50, Maxima=88, Median=16, 25th Percentile=2.6, 75th Percentile=38; Arms B/C: Minima=0.40, Maxima=55, Median=9.9, 25th Percentile=6.1, 75th Percentile=17. c ) %CD8 + T cells (% CD3 + CD8+ of CD45 + ). Arm A: Minima=4.3, Maxima=88, Median=37, 25th Percentile=22, 75th Percentile=47; Arms B/C: Minima=19, Maxima=91, Median=51, 25th Percentile=36, 75th Percentile=71. d ) % αβ T cells (% TCRαβ+ of CD3 + ). Arm A: Minima=8.2, Maxima=94, Median=69, 25th Percentile=28, 75th Percentile=86; Arms B/C: Minima=32, Maxima=98, Median=71, 25th Percentile=48, 75th Percentile=84. e ) % γδ T cells (% TCRγδ+ of CD3 + ). Arm A: Minima=5.1, Maxima=79, Median=28, 25th Percentile=8.4, 75th Percentile=67; Arms B/C: Minima=1.1, Maxima=83, Median=25, 25th Percentile=10, 75th Percentile=53. f ) % CD3 + CD16 + CD56+ of CD45 + . Arm A: Minima=2.8, Maxima=25, Median=11, 25th Percentile=7.2, 75th Percentile=17; Arms B/C: Minima=3.4, Maxima=64, Median=16, 25th Percentile=8.1, 75th Percentile=28. g ) % NK cells (CD16/CD56 + CD3- of CD45 + ). Arm A: Minima=0.40, Maxima=48, Median=1.0, 25th Percentile=0.48, 75th Percentile=4.6; Arms B/C: Minima=0.10, Maxima=62, Median=1.6, 25th Percentile=0.60, 75th Percentile=6.1. h - i ) IFNγ ELISpot with background correction for Arm A ( h ) and Arms B/C ( i ). Negative values after background normalization have been normalized to zero for visual representation.

    Article Snippet: An FcR blocking agent (Miltenyi Biotec, cat. no. 130-059-901) was added to the tubes for 5 min to prevent any nonspecific binding, followed by an appropriate antibody mix (shown in tables below), which was incubated in the dark for 15 min. Antibodies for the pan leukocyte panel included CD14 Vio Blue (Miltenyi Biotec, cat. no. 130-110-524), CD19 FITC (Miltenyi Biotec, cat. no. 130-113-646), CD16 PE (Miltenyi Biotec, cat. no. 130-113-393), CD56 PE (Miltenyi Biotec, cat. no. 130-113-312), CD3 Per CP Vio-770 (Miltenyi Biotec, cat. no. 130-113-141), CD4 PE-Vio-770 (Miltenyi Biotec, cat. no. 130-113-227), CD45 APC (Miltenyi Biotec, cat. no. 130-110-633) and CD8 APC Vio-770 (Miltenyi Biotec, cat. no. 130-110-681).

    Techniques: Enzyme-linked Immunospot, Whisker Assay

    ( A ) Young Pnpla2 fl/fl and Pnpla2 AdipoQΔ/Δ mice were infected with MA-SARS-CoV-2 and BM was analyzed for early hematopoiesis at 5 dpi. ( B ) Representative flow cytometry plots showing c-KIT vs . Sca-1 gating on lineage-negative (Lin − ) cells to identify LKS (Lin − c-Kit + Sca-1 + ) hematopoietic stem and progenitor cells. Percentage and absolute numbers of ( C ) LKS (Lin − cKIT + Sca-1 + ) and ( D ) c-KIT + (Lin − cKIT + Sca-1 − ) cells. (E) Representative flow cytometry plots showing CD48 vs. CD150 gating on LKS cells to identify long-term hematopoietic stem cells (LT-HSC: CD150 + CD48 − ), short-term HSC (ST-HSC: CD150 − CD48 − ) and multipotent progenitor 2 (MPP2: CD150 + CD48 + ). Percentage and absolute numbers of ( F ) LT-HSC, ( G ) ST-HSC and ( H ) MPP2 cells. ( I ) Representative flow cytometry plots showing CD135 vs . CD34 gating on MPP cells to identify MPP3 (CD135 − CD34 + ) and MPP4 (CD135 + CD34 + ). Percentage and absolute numbers of (J) MPP3 and (K) MPP4 cells. Data shown as mean ± SD (C, D, F, G, H, J, K). Circles represent individual mice (n=7-11 per group, males & females). p values determined using two-way ANOVA. NS, not significant; *p < 0.05. Data pooled from three independent experiments with a similar trend.

    Journal: bioRxiv

    Article Title: Age-dependent disease tolerance to SARS-CoV-2 infection

    doi: 10.64898/2026.06.27.734955

    Figure Lengend Snippet: ( A ) Young Pnpla2 fl/fl and Pnpla2 AdipoQΔ/Δ mice were infected with MA-SARS-CoV-2 and BM was analyzed for early hematopoiesis at 5 dpi. ( B ) Representative flow cytometry plots showing c-KIT vs . Sca-1 gating on lineage-negative (Lin − ) cells to identify LKS (Lin − c-Kit + Sca-1 + ) hematopoietic stem and progenitor cells. Percentage and absolute numbers of ( C ) LKS (Lin − cKIT + Sca-1 + ) and ( D ) c-KIT + (Lin − cKIT + Sca-1 − ) cells. (E) Representative flow cytometry plots showing CD48 vs. CD150 gating on LKS cells to identify long-term hematopoietic stem cells (LT-HSC: CD150 + CD48 − ), short-term HSC (ST-HSC: CD150 − CD48 − ) and multipotent progenitor 2 (MPP2: CD150 + CD48 + ). Percentage and absolute numbers of ( F ) LT-HSC, ( G ) ST-HSC and ( H ) MPP2 cells. ( I ) Representative flow cytometry plots showing CD135 vs . CD34 gating on MPP cells to identify MPP3 (CD135 − CD34 + ) and MPP4 (CD135 + CD34 + ). Percentage and absolute numbers of (J) MPP3 and (K) MPP4 cells. Data shown as mean ± SD (C, D, F, G, H, J, K). Circles represent individual mice (n=7-11 per group, males & females). p values determined using two-way ANOVA. NS, not significant; *p < 0.05. Data pooled from three independent experiments with a similar trend.

    Article Snippet: The cells were stained with the following primary antibodies: Sca-1 FITC (#122505), Ly6C PerCP/Cy5.5 (#128012), CD115 PE (#135505), CD34 PE/Cy5 (#119311), F4/80 AF647 (#123122), CD11C BV605 (#117333), CD3 Biotin (#100243), CD49b Biotin (#103521), CD90.1 Biotin (#202510), all from Biolegend, CD135 PerCPeF710 (#46-1351-82), CD150 eF450 (#48-1502-82), MHCII eF506 (#69-5321-82) from Invitrogen, CD48 PE-Vio 770 (Miltenyi Biotec S. L, #130-102-363), c-KIT APC (BD Pharmingen, #553356), CD19 Biotin (eBioscience, #553784), for 25 min (4°C).

    Techniques: Infection, Flow Cytometry

    ( A ) Young (3 months) and old (>20 months) mice were infected with MA-SARS-CoV-2 and BM was analyzed for early hematopoiesis at 5 dpi. ( B ) Representative flow cytometry plots showing c-KIT vs. Sca-1 gating on lineage-negative (Lin − ) cells to identify LKS (Lin − c-Kit + Sca-1 + ) hematopoietic stem and progenitor cells. Percentage and absolute numbers of ( C ) LKS cells and ( D ) c-KIT + (Lin − cKIT + Sca-1 − ) cells. ( E ) Representative flow cytometry plots showing CD48 vs. CD150 gating on LKS cells to identify long-term hematopoietic stem cells (LT-HSC: CD150 + CD48 − ), short-term HSC (ST-HSC: CD150 − CD48 − ), and multipotent progenitor 2 (MPP2: CD150 + CD48 + ). Percentage and absolute numbers of ( F ) LT-HSC, ( G ) ST-HSC and ( H ) MPP2 cells. ( I ) Representative flow cytometry plots showing CD135 vs. CD34 gating on MPP cells to identify MPP3 (CD135 − CD34 + ) and MPP4 (CD135 + CD34 + ). Percentage and absolute numbers of ( J ) MPP3 and ( K ) MPP4 cells. Data are shown as mean ± SD (C, D, F, G, H, J, K). Circles represent individual mice (n=6 per group, males). p values were determined using two-way ANOVA. NS, not significant; *p < 0.05, **p < 0.01; ***p < 0.001. Data pooled from two independent experiments with a similar trend.

    Journal: bioRxiv

    Article Title: Age-dependent disease tolerance to SARS-CoV-2 infection

    doi: 10.64898/2026.06.27.734955

    Figure Lengend Snippet: ( A ) Young (3 months) and old (>20 months) mice were infected with MA-SARS-CoV-2 and BM was analyzed for early hematopoiesis at 5 dpi. ( B ) Representative flow cytometry plots showing c-KIT vs. Sca-1 gating on lineage-negative (Lin − ) cells to identify LKS (Lin − c-Kit + Sca-1 + ) hematopoietic stem and progenitor cells. Percentage and absolute numbers of ( C ) LKS cells and ( D ) c-KIT + (Lin − cKIT + Sca-1 − ) cells. ( E ) Representative flow cytometry plots showing CD48 vs. CD150 gating on LKS cells to identify long-term hematopoietic stem cells (LT-HSC: CD150 + CD48 − ), short-term HSC (ST-HSC: CD150 − CD48 − ), and multipotent progenitor 2 (MPP2: CD150 + CD48 + ). Percentage and absolute numbers of ( F ) LT-HSC, ( G ) ST-HSC and ( H ) MPP2 cells. ( I ) Representative flow cytometry plots showing CD135 vs. CD34 gating on MPP cells to identify MPP3 (CD135 − CD34 + ) and MPP4 (CD135 + CD34 + ). Percentage and absolute numbers of ( J ) MPP3 and ( K ) MPP4 cells. Data are shown as mean ± SD (C, D, F, G, H, J, K). Circles represent individual mice (n=6 per group, males). p values were determined using two-way ANOVA. NS, not significant; *p < 0.05, **p < 0.01; ***p < 0.001. Data pooled from two independent experiments with a similar trend.

    Article Snippet: The cells were stained with the following primary antibodies: Sca-1 FITC (#122505), Ly6C PerCP/Cy5.5 (#128012), CD115 PE (#135505), CD34 PE/Cy5 (#119311), F4/80 AF647 (#123122), CD11C BV605 (#117333), CD3 Biotin (#100243), CD49b Biotin (#103521), CD90.1 Biotin (#202510), all from Biolegend, CD135 PerCPeF710 (#46-1351-82), CD150 eF450 (#48-1502-82), MHCII eF506 (#69-5321-82) from Invitrogen, CD48 PE-Vio 770 (Miltenyi Biotec S. L, #130-102-363), c-KIT APC (BD Pharmingen, #553356), CD19 Biotin (eBioscience, #553784), for 25 min (4°C).

    Techniques: Infection, Flow Cytometry